摘要
目的观察雾化吸入重组人干扰素α1b治疗儿童肠道病毒71型(EV71)手足口病的疗效。方法选取2016年4月至2017年3月西安市儿童医院和西安交通大学医学院第二附属医院收治的EV71手足口病患儿240例为研究对象(其中普通型和重型各120例),两组患儿以随机数字表和随机数余数分组法分别分为干扰素治疗组和对照组(各60例),并比较两型、两组患儿的临床表现、疗效及治疗前后血常规、白细胞介素(IL)及淋巴细胞亚群的变化。结果普通型患儿治疗组总有效率为(96.7%),显著高于对照组(85.0%),差异有统计学意义(χ^2=4.90、P=0.03)。热退时间、皮疹消退时间、口腔溃疡消退时间、正常进食时间及住院时间均短于对照组(P均<0.05)。治疗4 d后,白细胞、淋巴细胞、C-反应蛋白、IL-6和IL-10水平均显著低于对照组,差异均有统计学意义(P均<0.05)。治疗后CD3^+(t=5.13、P<0.001)、CD3^+CD4^+(t=2.66、P<0.001)和CD3^+CD8^+(t=2.13、P=0.02)水平显著高于对照组,差异均有统计学意义。重型患儿干扰素治疗组和对照组上述临床症状和指标比较结果与普通型患儿一致。结论雾化吸入重组人干扰素α1b能够改善EV71手足口病患儿的临床症状、细胞因子及淋巴细胞亚群水平。
Objective To investigate the clinical efficacy of recombinant human interferonα1b on children with hand,foot and mouth disease(HFMD)of Enterovirus 71(EV71)infection.Methods Total of 240 children with HFMD of EV71 infection including 120 severe cases and 120 mild cases were admitted in Xi’an Children’s Hospital and the Second Affiliated Hospital of Medical School,Xi’an Jiaotong University from April 2016 to March 2017,and then were divided into interferon treatment group and control group in each severe and mild group by random number table and random number remainder grouping.The clinical symptoms,curative effects and blood routine,cytokines and lymphocyte subsets levels before and after treatment were compared in each severe and mild group,respectively.Results Among the mild cases,the total effective rate of the interferon treatment group(96.7%)was significantly higher than that of the control group(85.0%),with significant difference(χ^2=4.90,P=0.03),but antipyretic time,rash subsidence time,oral ulcer subsidence time,normal eating time and hospitalization period of the cases in interferon treatment group were shorter than those of the control group,with significant differences(all P<0.05).After 4 days of treatment,the levels of white blood cells,lymphocytes,C-reactive protein,interleukin-6(IL-6)and IL-10 in interferon treatment group were significantly lower than those in control group(all P<0.05),and the levels of CD3^+(t=5.13,P<0.001),CD3^+CD4^+(t=2.66,P<0.001)and CD3^+CD8^+(t=2.13,P<0.001)were all significantly higher,all with significant differences.Among the severe cases,the comparetive results of the interferon treatment group and the control group were consistent with the mild cases.Conclusions Inhalation of recombinant human interferonα1b could improve the clinical symptoms and the levels of cytokines and lymphocyte subsets of children with HFMD of EV71 infection.
作者
袁娟
邓慧玲
李亚萍
吴媛
李梅
王军
张玉凤
党双锁
Yuan Juan;Deng Huiling;Li Yaping;Wu Yuan;Li Mei;Wang Jun;Zhang Yufeng;Dang Shuangsuo(Department of Infectious Diseases,the Second Affiliated Hospital of Medical School,Xi’an Jiaotong University,Xi’an 710004,China;The Second Department of Infectious Diseases,Xi’an Children’s Hospital,Xi’an 710003,China;Department of Critical Care Medicine,the Second Affiliated Hospital of Medical School,Xi’an Jiaotong University,Xi’an 710004,China)
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2019年第6期478-484,共7页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
国家自然科学基金(No.81701632)
陕西省重点项目(No.2017ZDXM-SF-07)
陕西省科技统筹重点产业创新链工程计划资助项目(No.2016KTZD SF02-04)
关键词
肠道病毒71型
手足口病
重组人干扰素Α1B
疗效
Enterovirus 71
Hand
foot and mouth disease
Recombinant human interferonα1b
Clinical efficacy
